TITLE

Clinical pharmacokinetics: brief reports

PUB. DATE
April 2006
SOURCE
Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely coadministered in diabetic patients, have a narrow efficacy/toxicity ratio or are known to induce or inhibit the cytochrome P450 system) may have important clinical implications. As metformin is not metabolised and does not inhibit the metabolism of other drugs, there are no clinically relevant metabolic interactions with this agent. However, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver and may be subject to drug-drug metabolic interactions, resulting in either hypoglycaemia or worsening of metabolic control
ACCESSION #
20254476

 

Related Articles

  • Effects of drug-drug interactions involving oral antihyperglycaemics are, with the exception of hypoglycaemia, mostly clinically unimportant.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p18 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • First reports of serious adverse drug reactions in recent weeks.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • Hypoglycemia: Still the Limiting Factor in the Glycemic Management of Diabetes. Philip Cryer // Endocrine Practice;Sep2008, Vol. 14 Issue 6, p750 

    Objective: To review the prevalence of, risk factors for, and prevention of hypoglycemia from the perspective of the pathophysiologic aspects of glucose counterregulation in diabetes.Methods: This review is based on personal experience and research and the relevant literature.Results: Although...

  • Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. Bodmer, Michael; Meier, Christian; Krahenbuhl, Stephan; Jick, Susan S.; Meier, Christoph R. // Diabetes Care;Nov2008, Vol. 31 Issue 11, p2086 

    OBJECTIVE -- Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs. RESEARCH DESIGN AND...

  • Drug-drug interaction between voriconazole and oral hypoglycemic agents in diabetic rats. Kumar, Boyina Hemanth; Joshi, Bheemachari; Hanish Singh, Jayasingh Chellammal; Diwan, Prakash V. // Indian Journal of Pharmacology;Mar/Apr2013, Vol. 45 Issue 2, p155 

    Objective: The objective was to study the of drug-drug interaction between voriconazole and oral hypoglycemic agents in normal and alloxan induced diabetic rats. Materials and Methods: The study was designed in two phases. In the first phase, influence of glibenclamide (0.45 mg/kg, p.o.) and...

  • Haemodynamic and Metabolic Effects of Low Daily Dose Sulphonylureas in Diabetic Dog Hearts. Posa, Ildiko; Kocsis, Erzsebet; Nieszner, Eva; Pogatsa, Gabor; Koltai, Maria Zsofia // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jul2002, Vol. 52 Issue 7, p552 

    The effects of glibenclamide (GB, CAS 10238-21-8) and those of the latest low dally dose sulphonylurea compound, glimepiride (GM, CAS 93479-97-1) on myocardial haemodynamics and pyruvatelactate metabolism of healthy and alloxan-diabetic dogs (n = 6 in six groups) were compared. Mean arterial...

  • Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus. Rajagopalan, Rukmini; Perez, Alfonso; Ye, Zhan; Khan, Mehmood; Murray, Frederick T. // Drugs & Aging;2004, Vol. 21 Issue 4, p259 

    Pioglitazone as monotherapy and in combination with sulfonylurea, metformin, or insulin has consistently demonstrated improved glycaemic and lipid parameters in patients with type 2 diabetes mellitus. Objective: We performed a subanalysis to examine the effect of pioglitazone on glycaemia and...

  • Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge. Langford, N.J.; Krentz, A.J.; Martin, U.; Elliott, S.; Ferner, R.E. // Postgraduate Medical Journal;Feb2003, Vol. 79 Issue 928, p120 

    Describes a case of severe relapsing sulphonylurea-induced hypoglycemia. Presumptive diagnosis of recurrent transient cerebral ischemic episodes; Capillary plasma glucose concentration; Increased pancreatic insulin secretion.

  • The Effectiveness of Metformin versus Glyburide in Type 2 Diabetes: Results from ADOPT (A Diabetes Outcomes Progression Trial). Herman, William H.; Haffner, Steven M.; Kahn, Steven E.; Zinman, Bernard; Holman, Rury R.; Viberti, Giancarlo F.; Lachin, John M.; Kravitz, Barbara G.; Heise, Mark A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA146 

    ADOPT compared initial oral monotherapies in recently diagnosed type 2 diabetic patients and found rosiglitazone to be superior to metformin (Met) and glyburide (Gly) as assessed by time to monotherapy failure (MF), defined as time to the first of two successive fasting plasma glucose (FPG)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics